北京市中伦律师事务所 关于北京赛科希德科技股份有限公司 2024 年年度股东大会的 法律意见书 致：北京赛科希德科技股份有限公司 根据《中华人民共和国公司法》《中华人民共和国证券法》等相关法律、法 规和规范性文件及《北京赛科希德科技股份有限公司章程》（以下简称"公司章 程"）的规定，北京市中伦律师事务所（以下简称"本所"）接受北京赛科希德 科技股份有限公司（以下简称"公司"）委托，对公司 2024 年年度股东大会（以 下简称"本次股东大会"）的相关事项进行见证并出具法律意见。 为出具本法律意见书，本所律师审查了公司提供的相关文件，该等文件包括 但不限于： 1. 现行有效的公司章程； 2. 公司刊登在上海证券交易所网站的公司董事会关于召开本次股东大会的 通知； 3. 公司本次股东大会股权登记日的股东名册、出席现场会议股东的到会登 记记录及凭证资料； 4. 公司本次股东大会的相关会议文件。 本所律师根据相关法律法规的要求，按照律师行业公认的业务标准、道德规 范和勤勉尽责精神，对公司本次股东大会的相关法律问题出具如下意见： 一、本次股东大会的召集与召开程序 本次股东大会由公司董事会召集。公司董事会已于 2025 年 ...

证券代码：688338 证券简称：赛科希德 公告编号：2025-025 北京赛科希德科技股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 79 | | --- | --- | | 普通股股东人数 | 79 | | 2、出席会议的股东所持有的表决权数量 | 50,790,657 | | 普通股股东所持有表决权数量 | 50,790,657 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比例（%） | 47.8514 | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 47.8514 | （四） 表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 本次股东大会由公司董事会召集，董事长吴仕明先生主持，会议采用现场投 （一） 股东大会召开的时间 ...

Core Insights - The behavior of margin traders has attracted significant market attention, with investors hoping to capture investment opportunities from their activities [1] Group 1: Margin Trading Data - On May 8, a total of 3,663 stocks received margin buying funds, with the top three stocks being Xinyi Technology (¥1.425 billion), Zhongji Xuchuang (¥1.053 billion), and Shenghong Technology (¥807 million) [1] - The table lists stocks with the highest margin buying amounts, including Tiancheng Technology (¥15.75 million), Xingqiu Graphite (¥8.83 million), and Lianyu Co. (¥15.27 million), showing their respective transaction amounts and margin buying ratios [1] - Margin buying accounted for significant percentages of total transaction amounts for various stocks, with Tiancheng Technology at 28.65%, Xingqiu Graphite at 28.51%, and Lianyu Co. at 28.15% [1] Group 2: Stock Performance - The price changes of stocks with high margin buying varied, with some stocks experiencing gains, such as Tiancheng Technology (1.47%) and Xingqiu Graphite (2.39%), while others like Fuliwang saw a decline (-3.29%) [1][2] - The data indicates that margin buying can correlate with stock performance, as seen in the fluctuations of the stocks listed [1][2]

北京赛科希德科技股份有限公司 2024 年年度股东大会 会议资料 二〇二五年五月 北京赛科希德科技股份有限公司 2024 年年度股东大会会议资料 目录 证券代码：688338 证券简称：赛科希德 五、股东及股东代理人要求在股东大会现场会议上发言的，应当于股东大会 召开前一天向大会会务组进行登记。大会主持人根据会务组提供的名单和顺序安 排发言，现场要求提问的股东及股东代理人，应当按照会议的议程举手示意，经 会议主持人许可方可提问。有多名股东及股东代理人同时要求发言时，先举手者 发言；不能确定先后时，由主持人指定发言者。 | 北京赛科希德科技股份有限公司 | | 2024 年年度股东大会会议须知 3 | | --- | --- | --- | | 北京赛科希德科技股份有限公司 | | 2024 年年度股东大会会议议程 5 | | 北京赛科希德科技股份有限公司 | | 2024 年年度股东大会会议议案 7 | | 议案一 | 关于《2024 | 年年度报告》及摘要的议案 7 | | 议案二 | 关于《2024 | 年度董事会工作报告》的议案 8 | | 议案三 | 关于《2024 | 年度监事会工作报告》的议案 1 ...

证券代码：688338 证券简称：赛科希德 公告编号：2025-024 北京赛科希德科技股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/6/28，由董事长吴仕明先生提议 | | | | | | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2024 年 月 日~2025 月 25 日 | 6 | 26 | 年 | 6 | | 预计回购金额 | 5,000万元~10,000万元 | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | | | | | □为维护公司价值及股东权益 | | | | | | 累计已回购股数 | 2,172,456股 | | | | | | 累计已回购股数占总股本比例 | 2.0467% | | | | | | 累计已回购金额 | 51,100,586.60元 | | | | | ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating a projected investment return exceeding the market benchmark by more than 15% over the next 6-12 months [5]. Core Insights - The company achieved a revenue of 306 million yuan in 2024, reflecting a year-on-year growth of 11.03%. However, the net profit attributable to shareholders decreased by 3.35% to 113 million yuan [1][2]. - In Q1 2025, the company reported a revenue of 68.64 million yuan, down 9.47% year-on-year, with a net profit of 23.13 million yuan, a decline of 23.98% [1][2]. - The revenue growth in 2024 was primarily driven by an increase in the installation and user base of coagulation products, alongside rising demand for thrombus and hemostasis testing [2]. - The company is focusing on increasing R&D investment, which reached 19.60 million yuan in 2024, a growth of 2.23% year-on-year, and has introduced several new medical device registrations [2][3]. - The domestic market accounted for over 95% of the company's revenue in 2024, benefiting from the trend of domestic product substitution due to cost control policies in healthcare [3]. Summary by Sections Financial Performance - In 2024, the company reported a revenue of 306 million yuan, with a growth rate of 11.03%. The net profit attributable to shareholders was 113 million yuan, showing a decline of 3.35% [4]. - For Q1 2025, the revenue was 68.64 million yuan, down 9.47% year-on-year, and the net profit was 23.13 million yuan, a decrease of 23.98% [1][2]. R&D and Product Development - The company increased its R&D expenditure to 19.60 million yuan in 2024, marking a 2.23% increase from the previous year. New product registrations include lupus anticoagulant testing kits and quality control products [2][3]. Market Position and Strategy - The company has established a nationwide distribution network covering 29 provinces and key cities, with a strong presence in both tertiary hospitals and grassroots medical institutions [3]. - The overseas market revenue grew by 11.05% in 2024, indicating the initial success of the company's global expansion strategy [3]. Profitability and Valuation - The report projects a net profit of 126 million yuan for 2025, reflecting a growth rate of 11.71%, with a PE ratio of 20 for 2025 [4][10].

Core Viewpoint - The company, Beijing Saikexide Technology Co., Ltd., focuses on the research, development, production, and sales of diagnostic instruments, reagents, and consumables in the field of thrombosis and hemostasis, aiming to provide automated testing solutions for medical institutions [7][28]. Company Overview - The company has established a core technology cluster covering instruments, reagents, and consumables, with five major technology categories including blood rheology measurement technology and coagulation diagnostic testing technology [25][28]. - The company has 45 patents, including 14 invention patents, and has received multiple awards for its technological advancements [26]. Business Model - The company operates on a "self-research and production, sales-driven production, and mainly distribution" model, which aligns with industry practices and its development stage [9][14]. - The procurement model is based on "production-driven ordering," ensuring quality through long-term partnerships with qualified suppliers [10]. - The production model is "sales-driven production," allowing for adjustments based on market conditions and inventory [11]. Industry Analysis - The in vitro diagnostic market in China has shown a compound annual growth rate (CAGR) of 18.6% from 2014 to 2018, with the market size exceeding 100 billion RMB in 2021 [16]. - The thrombosis and hemostasis in vitro diagnostic market is in a rapid development phase, with a CAGR of 24.8% from 2015 to 2019 [16]. - The demand for coagulation testing is expected to grow due to factors such as population aging and advancements in medical technology, despite a temporary slowdown from 2020 to 2022 [16]. Technological Trends - The industry is characterized by high technical content and rapid growth, with a significant focus on innovation and new product development [17][18]. - The clinical application of thrombosis and hemostasis testing is evolving towards disease prevention, diagnosis, and drug monitoring, driven by advancements in direct oral anticoagulants (DOACs) [29][30]. Financial Highlights - The company plans to distribute a cash dividend of 3.3 RMB per 10 shares, totaling approximately 34.31 million RMB, which represents 30.36% of the net profit attributable to shareholders [4][5].

Core Viewpoint - Beijing Saike Xide Technology Co., Ltd. (hereinafter referred to as "Saike Xide") has released its 2024 annual report, showcasing resilience amid challenges such as medical insurance cost control policies and market competition while also highlighting significant financial metrics and business developments [1]. Financial Performance - Revenue increased to CNY 305,870,242.02, a growth of 11.03% year-on-year, driven by an increase in coagulation product installations and user numbers [2]. - Net profit attributable to shareholders decreased by 3.35% to CNY 112,999,583.01, primarily due to increased depreciation, operational maintenance, and relocation costs following the commissioning of new production facilities [2]. - The non-recurring net profit was CNY 110,486,685.01, down 3.97% year-on-year, indicating a decline in core business profitability [2]. Expense Changes - Sales expenses rose by 6.52% to CNY 37,294,513.91, reflecting continued investment in market expansion [3]. - Management expenses surged by 90.55% to CNY 25,773,452.43, largely due to increased costs associated with new facility operations [3]. - Financial expenses were reported as -CNY 25,208,978.88, indicating a decrease in interest income due to lower bank deposit rates [3]. - R&D expenses amounted to CNY 19,604,679.27, a 2.23% increase, emphasizing the company's commitment to innovation [3]. Cash Flow Situation - Net cash flow from operating activities was CNY 122,983,903.25, up 12.17%, indicating improved cash generation capabilities [4]. - Net cash flow from investing activities was -CNY 269,818,221.94, reflecting increased outflows for structured deposit investments [4]. - Net cash flow from financing activities was -CNY 67,102,623.91, primarily due to share buybacks [4]. R&D and Market Conditions - R&D investment was CNY 19,604,679.27, accounting for 6.41% of revenue, showing a slight decrease in proportion but an absolute increase in spending [5]. - The company achieved several R&D milestones, including new product registrations, enhancing its product portfolio and market competitiveness [5]. - The company is actively expanding its market presence and optimizing channel policies, with a growing number of domestic users and installations [5]. - The competitive landscape in the thrombosis and hemostasis in vitro diagnostics market is intensifying, posing challenges to the company's operations [5].

4月24日赛科希德发布2024年度分配预案，拟10派3.3元（含税），预计派现金额合计为3431.01万元。派 现额占净利润比例为30.36%，这是公司上市以来，累计第5次派现。 公司上市以来历次分配方案一览 | 日期 | 分配方案 | 派现金额合计（亿元） | 股息率（%） | | --- | --- | --- | --- | | 2024.12.31 | 10派3.3元（含税） | 0.34 | 1.32 | | 2023.12.31 | 10派2.6元（含税） | 0.28 | 0.62 | | 2022.12.31 | 10转增3派2.6元（含税） | 0.21 | 0.72 | | 2021.12.31 | 10派2.5元（含税） | 0.20 | 0.48 | | 2020.12.31 | 10派4元（含税） | 0.33 | 0.39 | 证券时报•数据宝统计显示，公司今日公布了2024年报，共实现营业收入3.06亿元，同比增长11.03%， 实现净利润1.13亿元，同比下降3.35%，基本每股收益为1.07元，加权平均净资产收益率为6.91%。 资金面上看，该股今日主力资金净流入85.64万 ...

文件编号：SUC/YQ-01 版本：A0 北京赛科希德科技股份有限公司 舆情管理制度 （第四届董事会第二次会议审议通过） 第一章 总则 第一条 为了提高北京赛科希德科技股份有限公司（以下简称"公司"）应对 各类舆情的能力，建立快速反应和应急处置机制，及时、妥善处理各类舆情对公 司股价、商业信誉及正常经营活动造成的影响，切实保护投资者合法权益，根据 《上海证券交易所科创板股票上市规则》及相关法律法规和《北京赛科希德科技 股份有限公司章程》（以下简称《公司章程》）等相关规定，结合公司实际情况， 制订本制度。 第二条 本制度所称舆情包括但不限于：社会公众、各类媒体等发布的可能对 公司形象、对公司投资者的价值判断和投资决策产生影响，可能引发公司股票及 其衍生品交易价格产生较大波动的评论、报道或传言等。 第三条 舆情信息的分类： （一）重大舆情：指传播范围较广，对公司正常经营活动及企业形象造成较 大影响，造成公司股票及其衍生品种交易异常波动的舆情； （二）一般舆情：指除重大舆情外的其他舆情。 第四条 本制度适用于公司及各分支机构、合并报表范围内的子公司。 第二章 舆情管理机构及其职责 第五条 董事会秘书负责舆情监测分析 ...